Table 5 Characteristics of the studies included in the systematic review about Cmin (adults)
Study | Design of study | Country of study | Duration of therapy (days) | Age of patients | No. of patients | Cmin (μg/ml) of patients | |
|---|---|---|---|---|---|---|---|
Thrombocytopenia | Non-thrombocytopenia | ||||||
Alffenaar 2010 [45] | Prospective pharmacokinetic study | Netherlands | Median: 56 | Median: 28 | 8 (0/8) | ― | Median: 5.8 |
Alffenaar 2010 [65] | Prospective pharmacokinetic study | Netherlands | Median: 49 | Median: 28 | 12 (0/12) | ― | Median: 4.4 |
Beer 2007 [46] | Prospective study | Austria | > 7 | Mean: 49.2 ± 19.5 | 5 (0/5) | ― | Mean: 1.94 ± 1.69 |
Cojutti 2019 [58] | Prospective interventional study | Italy | Median: 19-54 | Median: 62 | 61 (9/52) | 4.28, 6.81, 7.32, 9.9, 10.0, 11.43, 14.83, 16.43, 27.88 | ― |
Conte 2002 [50] | Prospective study | America | 2.5 | Mean: 30 ± 5 | 25 (0/25) | ― | Mean: 0.2 ± 0.2 |
Dong 2014 [23] | Retrospective observational study | China | Mean: 11.3 ± 5.7 | Mean: 58.6 ± 19.9 | 70 (31/39) | Median: 8.81 | Median: 2.88 |
Fang 2020 [59] | Prospective observational study | China | Mean: 10.0 ± 5.3 | Mean: 69.6 ± 13.8 | 84 (18/66) | 7.85 (50% probability) 10.55 (95% probability) | ― |
Hiraki 2012 [25] | Prospective study | Japan | Mean: 14.3 ± 11.0 | Mean: 64.6 ± 10.9 | 8 (5/3) | higher than 22.1 μg/ml (50% hazard ratio) | ― |
Luque 2014 [53] | Prospective pharmacokinetic study | Spain | > 3 | Mean: 51.9 ± 10.3 | 11 (0/11) | ― | <0.2-2 |
Luque 2019 [60] | Retrospective observational study | Spain | Median: 9 (cases with liver cirrhosis) 11 (controls) | Median: 67.5 (cases with liver cirrhosis) 61.5 (controls) | 52 (21/31) | Median: 20.4 | Median: 4.9 |
Matsumoto 2014 [61] | Prospective observational study | Japan | Mean: 12.9 ± 6.4 | Mean: 70.6 ± 10.3 | 44 (35/9) | 8.2 (50% probability) | ― |
Morata 2013 [62] | Retrospective study | Spain | 3-10 | Mean: 60.8 ± 17.4 (Cmin<2 mg/L) 66.8 ± 16.6 (Cmin>2 mg/L) | 78 (6/72) | Median: 12.9 | Median: 4.2 |
Myrianthefs 2006 [54] | Prospective study | Greece | ≧2 | Mean: 58.7 ± 17.3 | 14 (0/14) | ― | Mean: 5.6 ± 5.0 |
Nukui 2013 [63] | Prospective observational study | Japan | Median: 12 | Median: 46 | 30 (17/13) | day3: 13.4, day7: 15.3, day14: 15.2 threshold value > 7.5 | day3: 4.3, day7: 3.8, day14: 5.0 |
Pea 2012 [16] | Retrospective observational study | Italy | Median: 63 | Mean: 49.9 ± 15.2 | 35 (16/19) | 6.53 (50% probability) 9.96 (95% probability) | ― |
Swoboda 2010 [55] | Retrospective study | Germany | 2-4 | Mean: 57.2 ± 11.9 (septic patients on extended dialysis) 68.6 ± 4.2 (septic patients without dialysis) | 15 (0/15) | ― | Median: 1.0 (with dialysis) 0.5 (without dialysis) |
Tsuji 2011 [64] | Prospective observational study | Japan | Mean: 12.0 ± 10.2 | Mean: 66.9 ± 6.6 | 12 (2/10) | mean:35.4 ± 13.5 (Grade2) mean:67.7 ± 17.1 (Grade4) | ― |